Lieff Cabraser partner Paulina do Amaral will be a speaker at the American Association for Justice 2024 Winter Convention, taking place February 10-13, 2024 at the JW Marriot Austin in Austin, Texas. On day three of the convention, Paulina will participate in a panel discussion on “The Opioid Crisis in America: Exploring the Legal Solutions,” featuring the
The law firms of Lieff Cabraser Heimann & Bernstein LLP, Robbins Geller Rudman & Dowd LLP, Simmons Hanly Conroy LLC, Motley Rice LLC, and Browne Pelican PLLC, counsel for plaintiffs in the McKinsey opioids litigation, announce that U.S. District Court Judge Charles Breyer has granted final approval to a $230 million settlement by McKinsey &
On Wednesday, January 17, 2024, a distribution of $32 million was made to federally-recognized Native American Tribes as part of the McKinsey Opioid Epidemic Tribal Settlement. Lieff Cabraser serves as Plaintiffs’ lead counsel in the McKinsey & Co. National Prescription Opiate Litigation, and has been at the forefront of this crucial legal battle, striving to
Dedicated $39.5 million portion of proposed national $269.5 million McKinsey opioids settlement will go to Native American Tribes Global management and consulting company McKinsey & Co. describes itself as “the trusted advisor to the world’s leading businesses, governments, and institutions.” The company was sued in the wake of the national opioids harm litigation for its
Litigation to date has recovered more than $50 billion for communities nationwide to address and abate opioid epidemic June 8, 2023 – An additional $18.75 billion will now be provided to communities nationwide to directly address the opioid epidemic, as a vast majority of state and local governments confirmed participation in global settlements that resolve
As reported by Law360, a pivotal legal victory has been achieved in the fight against the U.S. opioid crisis, with Walgreens agreeing to a $230 million payment to the city of San Francisco. The payment is the culmination of an intense bench trial which established Walgreens’ culpability for its part in the city’s opioid epidemic.
The California Daily Journal’s 2023 CLAY award recognizes Lieff Cabraser, Robbins Geller, and the San Francisco City Attorney’s Office for their collective efforts in winning a landmark opioids bench trial against Walgreens pharmacy for substantially contributing to the opioid epidemic in San Francisco We are proud to announce that the California Daily Journal/California Lawyer has
On February 8, 2023, Judge Robert B. Kugler of the U.S. District Court for the District of New Jersey appointed Lieff Cabraser partner Rachel Geman as one of Class Counsel for the Medical Monitoring class in In re Valsartan, Losartan, and Irbesartan Products Liability Litigation, No. 19-2875 (RBK/SAK).
The Recorder has published an in-depth piece on Lieff Cabraser partner Richard M. Heiman highlighting his recent hard-fought work successfully representing the City of San Francisco in a landmark opioid bench trial against Walgreens pharmacy for its role in the City’s current drug crisis. In August 2022, the Court in the bench trial found Walgreens liable for
Federal judge finds Walgreens liable for substantially contributing to the opioid crisis in San Francisco SAN FRANCISCO (August 10, 2022) — San Francisco City Attorney David Chiu announced today that San Francisco acting on behalf of the People of the State of California won its landmark opioid trial against Walgreens pharmacy. Judge Charles R. Breyer